IRTC:NSD-iRhythm Technologies Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 75.04

Change

0.00 (0.00)%

Market Cap

USD 2.37B

Volume

0.71M

Analyst Target

USD 222.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 27.48B
PODD Insulet Corporation

N/A

USD 16.52B
BRKR Bruker Corporation

N/A

USD 8.98B
MASI Masimo Corporation

N/A

USD 7.71B
PRCT Procept Biorobotics Corp

N/A

USD 4.99B
TMDX TransMedics Group Inc

N/A

USD 4.17B
AXNX Axonics Modulation Technologie..

N/A

USD 3.60B
NARI Inari Medical Inc

N/A

USD 2.85B
LIVN LivaNova PLC

N/A

USD 2.80B
QDEL Quidel Corporation

N/A

USD 2.62B

ETFs Containing IRTC

FDHT:XETRA Fidelity Digital Health U.. 2.58 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.90% 31% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.90% 31% F 25% F
Trailing 12 Months  
Capital Gain -9.89% 34% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.89% 34% F 31% F
Trailing 5 Years  
Capital Gain 5.65% 58% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.65% 58% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 16.69% 57% F 70% C-
Dividend Return 16.69% 57% F 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 81.66% 45% F 25% F
Risk Adjusted Return 20.44% 75% C 54% F
Market Capitalization 2.37B 91% A- 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector